Bristol-Myers Squibb Company Stock Price and Value Analysis

Bristol-Myers Squibb Company (NYSE:BMY) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Bristol-Myers Squibb Company to reach your target.

Target type

BMY Free Cash Flow Trend

Free Cash Flow trendline for BMY
Free Cash Flow trendline for Bristol-Myers Squibb Company
CSV

Based on historical returns, we believe that Bristol-Myers Squibb Company can grow its free cash at a rate of about 15%. That's positive!

AdvantagesDisadvantages
  • This company has a large dividend yield!
  • This company is making money at a great rate!
  • This company is very stable.
  • This stock looks overpriced.
  • This company has wild ups and downs.

Inside the BMY Numbers

BMY Price
(Bristol-Myers Squibb Company stock price per share)
$58.80
[?] BMY Fair Price
(based on intrinsic value)
$31.70
[?] BMY Safety Price (based on a variable margin of safety) $25.36
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 35% lower than other Healthcare stocks
[?] PE Ratio versus Industry 71% higher than other Drug Manufacturers - General stocks
[?] Cash Yield 1.15%
[?] Free Cash Flow Jitter 37%
[?] Dividend Yield 4.32% (tax impact)
Shares Shorted 46,849,171

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 46,849,171 shares shorted. With 2,040,876,616 shares available for purchase and an average trading volume over the past 10 trading days of 9,959,890, it would take at least 4.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 14272 2,310
2008 14272 2,815
2009 14272 3,227
2010 14272 3,757
2011 14272 4,179
2012 14272 6,339
2013 14272 3,024
2014 14272 2,668
2015 14272 1,545
2016 14272 2,329
2017 14272 4,444
2018 14272 6,153
2019 14272 7,235
2020 14272 13,090
2021 14272 15,293
2022 14272 12,140
2023 14272 12,882
2024 14272 14,130
2025 14272 12,984

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 17 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $116,893 million against net income of $75,150 million, or 1.56 times. Net income was negative in 2 of the 19 years, and those years are left out of the ratio.

In 2025, operating cash flow was 2.01 times net income, compared with 0.61 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $1,311 million, 9.3% of operating cash flow of $14,156 million, which leaves an estimated $12,845 million after capex. Across the 19 years with reported capex, it averaged 11.2% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 2,165 3,153 843 1.46
2008 5,247 3,707 941 0.71
2009 10,612 4,065 730 0.38
2010 3,102 4,491 424 1.45
2011 3,709 4,840 367 1.30
2012 1,960 6,941 548 3.54
2013 2,563 3,545 537 1.38
2014 2,004 3,148 526 1.57
2015 1,565 2,105 820 1.35
2016 4,457 3,058 1,215 0.69
2017 1,007 5,275 1,055 5.24
2018 4,920 7,066 951 1.44
2019 3,439 8,210 836 2.39
2020 -9,015 14,052 753 n/a
2021 6,994 16,207 973 2.32
2022 6,327 13,066 1,118 2.07
2023 8,025 13,860 1,209 1.73
2024 -8,948 15,190 1,248 n/a
2025 7,054 14,156 1,311 2.01

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $100,680 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $38,173 million, 37.9% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 9 of those 10 years.

In 8 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $31,309 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends paid were $5,045 million, 38.9% of estimated free cash flow of $12,984 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 2,329 2,547 231 2,778 119.3%
2017 4,444 2,577 2,469 5,046 113.5%
2018 6,153 2,613 320 2,933 47.7%
2019 7,235 2,679 7,300 9,979 137.9%
2020 13,090 4,075 1,546 5,621 42.9%
2021 15,293 4,396 6,287 10,683 69.9%
2022 12,140 4,634 8,001 12,635 104.1%
2023 12,882 4,744 5,155 9,899 76.8%
2024 14,130 4,863 n/a 4,863 34.4%
2025 12,984 5,045 n/a 5,045 38.9%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $15,617 million in 2007 and $48,194 million in 2025, a compound annual growth rate of 6.5% over 18 years.

Revenue fell 0.2% from 2024 to 2025.

Our estimated free cash flow was $12,984 million in 2025, 26.9% of revenue. In 2007 the estimated margin was 14.8%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 15,617 2,310 14.8%
2008 17,715 2,815 15.9%
2009 18,808 3,227 17.2%
2010 19,484 3,757 19.3%
2011 21,244 4,179 19.7%
2012 17,621 6,339 36.0%
2013 16,385 3,024 18.5%
2014 15,879 2,668 16.8%
2015 16,560 1,545 9.3%
2016 19,427 2,329 12.0%
2017 20,776 4,444 21.4%
2018 22,561 6,153 27.3%
2019 26,145 7,235 27.7%
2020 42,518 13,090 30.8%
2021 46,385 15,293 33.0%
2022 46,159 12,140 26.3%
2023 45,006 12,882 28.6%
2024 48,300 14,130 29.3%
2025 48,194 12,984 26.9%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $10,209 million against total liabilities of $71,532 million, or 14.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 79.4% of total assets in 2025, compared with 58.6% in 2008, an increase of 20.8 percentage points.

Stockholders equity was $18,506 million in 2025, compared with $12,208 million in 2008, a rise of 51.6%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 23.0% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 29,486 7,976 17,278 12,208
2009 31,008 7,683 16,223 14,785
2010 31,076 5,033 15,438 15,638
2011 30,851 5,776 17,069 15,867
2012 32,408 1,656 19,651 13,638
2013 35,958 3,586 24,893 15,236
2014 33,424 5,571 18,218 14,983
2015 33,579 2,385 16,059 14,424
2016 31,892 4,237 19,156 16,347
2017 32,937 3,910 19,016 11,847
2018 33,083 5,342 22,080 14,127
2019 34,834 7,335 114,627 51,698
2020 118,481 14,546 80,599 37,882
2021 109,314 13,979 73,308 36,006
2022 96,820 9,123 65,702 31,118
2023 95,159 11,464 65,674 29,485
2024 92,603 10,346 76,215 16,388
2025 90,038 10,209 71,532 18,506

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $58.80, our model's value equals that price if free cash flow grows an average of 25.6 percent a year over the 10 projection years. Our model assumes 14.8 percent a year for this stock, so the price implies growth of 25.6 percent, which is above the 14.8 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

At 25.6 percent a year, free cash flow would grow about 9.8 times over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $1,386 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $47.04 21.8%
Current price $58.80 25.6%
20 percent above the current price $70.56 28.6%
Our model (stored fair price) $31.70 14.8%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Free cash flow was positive in all 19 fiscal years we have for Bristol-Myers Squibb Company under its current SEC filer.

Bristol-Myers Squibb Company is priced at $58.80, above our fair value estimate of $31.70 and its safe value of $25.36.

Bristol-Myers Squibb Company's average free cash flow rose sharply, from $2,784 million in its earliest three years to $13,332 million in its latest three.

Free cash flow is volatile from year to year, with a variability measure of 37%.

Bristol-Myers Squibb Company yields 4.32% in dividends.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 35% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 71% above the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Bristol-Myers Squibb Company, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Bristol-Myers Squibb Company (BMY) 120,192 13.0 4.3% 1.2% 85% above
Regeneron Pharmaceuticals (REGN) 95,243 20.4 0.4% 0.5% 133% above
Pfizer (PFE) 156,176 39.1 7.8% 11.6% 63% below
Abbott Laboratories (ABT) 178,390 38.4 2.4% 1.9% 49% above
Teva Pharmaceutical Industries Limited (TEVA) 44,970 89.6 - 13.5% 47% below
Zoetis (ZTS) 32,144 13.5 2.6% - 865% above
United Therapeutics Corporation (UTHR) 23,625 20.9 - 1.5% 30% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 14272.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: BMY annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in BMY

Does Bristol-Myers Squibb Company have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: BMY

This example shows how we apply the Trendshare checklist to BMY: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 58.80
    • Market cap: $120B
    • EPS: 4.51
  2. Step 2 — Valuation checks

    • P/E: 13.038
    • FCF yield: 1.2%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.